APA
Bartz R., Fukuchi K., Ohtsuka T., Lange T., Gruner K., Watanabe I., Hayashi S., Oda Y., Kawaida R., Komori H., Kashimoto Y., Wirtz P., Mayer J. A., Redondo-Müller M., Saito S., Takahashi M., Hanzawa H., Imai E., Martinez A., Hanai M., Häussinger D., Chapman R. W., Agatsuma T., Bange J. & Abraham R. (20200609). Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. : Molecular cancer therapeutics.
Chicago
Bartz René, Fukuchi Keisuke, Ohtsuka Toshiaki, Lange Tanja, Gruner Katrin, Watanabe Ichiro, Hayashi Shinko, Oda Yoko, Kawaida Reimi, Komori Hironobu, Kashimoto Yoshinori, Wirtz Peter, Mayer Jan-Peter A, Redondo-Müller Mauricio, Saito Shuntaro, Takahashi Mizuki, Hanzawa Hiroyuki, Imai Emi, Martinez Alberto, Hanai Masaharu, Häussinger Dieter, Chapman Roger W, Agatsuma Toshinori, Bange Johannes and Abraham Reimar. 20200609. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. : Molecular cancer therapeutics.
Harvard
Bartz R., Fukuchi K., Ohtsuka T., Lange T., Gruner K., Watanabe I., Hayashi S., Oda Y., Kawaida R., Komori H., Kashimoto Y., Wirtz P., Mayer J. A., Redondo-Müller M., Saito S., Takahashi M., Hanzawa H., Imai E., Martinez A., Hanai M., Häussinger D., Chapman R. W., Agatsuma T., Bange J. and Abraham R. (20200609). Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. : Molecular cancer therapeutics.
MLA
Bartz René, Fukuchi Keisuke, Ohtsuka Toshiaki, Lange Tanja, Gruner Katrin, Watanabe Ichiro, Hayashi Shinko, Oda Yoko, Kawaida Reimi, Komori Hironobu, Kashimoto Yoshinori, Wirtz Peter, Mayer Jan-Peter A, Redondo-Müller Mauricio, Saito Shuntaro, Takahashi Mizuki, Hanzawa Hiroyuki, Imai Emi, Martinez Alberto, Hanai Masaharu, Häussinger Dieter, Chapman Roger W, Agatsuma Toshinori, Bange Johannes and Abraham Reimar. Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. : Molecular cancer therapeutics. 20200609.